Ovarian
DESTINY-Ovarian01
Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy as First‑line Maintenance Therapy in HER2‑Expressing Ovarian Cancer
Trial overview
Clinical Area
Medical Oncology
Disease
Ovarian
Disease site
Gynaecology
Study Phase
III
Trial Identifiers
Registration number: NCT06819007
GenesisCare Location(s)
Principal Investigator(s)
Clinical trials enquiries